TAK trades at Wall Street's consensus target of —.
Last 12 months price action with 12-month analyst target path
The base valuation assumes TAK achieves its forward estimates and maintains a stable P/E multiple of 0.3x. This scenario reflects the blended consensus of 6 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of November 8, 2026, Takeda Pharmaceutical Company Limited (TAK) has a Wall Street consensus price target of N/A, based on estimates from 6 covering analysts. The company has a market capitalization of $66.87B.
Analyst price targets range from a low of N/A to a high of N/A.
The current analyst consensus rating is Buy, with 5 analysts rating the stock as a Buy or Strong Buy,1 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, TAK trades at a trailing P/E of 52.1x and forward P/E of 0.3x. Analysts expect EPS to grow -36.5% over the next year.
Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $3946.75, with bear and bull scenarios of $2486.45 and $5200.23 respectively. Model confidence stands at 40/100, suggesting limited visibility into future performance.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 NVONovo Nordisk A/S | $179.0B | $40.31 | $42.33 | +5.0% | Buy | 1.8x | 39 |
 AZNAstraZeneca PLC | $144.5B | $186.43 | $186.67 | +0.1% | Buy | 18.2x | 41 |
 SNYSanofi | $113.0B | $47.04 | $49.00 | +4.2% | Hold | 11.4x | 27 |
 NVSNovartis AG | $309.0B | $162.55 | $149.50 | -8.0% | Hold | 18.3x | 25 |
 GSKGSK plc | $100.8B | $50.33 | $57.95 | +15.1% | Hold | 13.9x | 29 |
 ABBVAbbVie Inc. | $514.7B | $291.31 | $308.88 | +6.0% | Buy | 20.9x | 44 |
 BMYBristol-Myers Squibb Company | $126.9B | $62.14 | $66.08 | +6.3% | Hold | 9.6x | 42 |
 JNJJohnson & Johnson | $664.9B | $276.22 | $285.31 | +3.3% | Buy | 24.9x | 40 |
 MRKMerck & Co., Inc. | $362.3B | $146.71 | $160.47 | +9.4% | Buy | 53.0x | 38 |
 PFEPfizer Inc. | $167.5B | $29.39 | $31.13 | +5.9% | Hold | 9.8x | 40 |
Quick answers to the most common questions about buying TAK stock.
The consensus price target for TAK is $N/A, close to the current price of $21.02 (N/A% implied move). Based on 6 analyst estimates, the stock appears fairly valued near current levels.
TAK has a consensus rating of "Buy" based on 6 Wall Street analysts. The rating breakdown is predominantly bullish, with 5 Buy/Strong Buy ratings. The consensus 12-month price target of $N/A implies N/A% upside from current levels.
With a forward P/E of 0.275x, TAK trades at a relatively low valuation. The consensus target of $N/A implies N/A% appreciation, suggesting the market may be pricing in risks.
The most bullish Wall Street analyst has a price target of $N/A for TAK, while the most conservative target is $N/A. The consensus of $N/A represents the median expectation. Our quantitative valuation model projects a bull case target of $5200 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.
TAK is moderately covered, with 6 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 5 have Buy ratings, 1 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month TAK stock forecast based on 6 Wall Street analysts shows a consensus price target of $N/A, with estimates ranging from $N/A (bear case) to $N/A (bull case). The median consensus rating is "Buy". Our proprietary valuation model produces a base case fair value of $3947, with bear/bull scenarios of $2486/$5200.
Our quantitative valuation model calculates TAK's fair value at $3947 (base case), with a bear case of $2486 and bull case of $5200. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 40/100.
TAK trades at a forward P/E ratio of 0.3x based on next-twelve-months earnings estimates compared to a trailing P/E of 52.1x. The lower forward P/E indicates analysts expect earnings growth. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
TAK appears fairly valued according to analysts, with a "Buy" rating and minimal upside to the $N/A target. Consider your investment thesis and risk tolerance. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
TAK analyst price targets range from $N/A to $N/A, a NaN% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $N/A consensus represents the middle ground. Our model's $2486-$5200 range provides an independent fundamental perspective.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.